What Is Driving Adheris Health (ASX:AHE) Shares Up 7% Today?

Sonal Goyal

23 October 2026 01:21 PM AEDT

What Is Driving Adheris Health (ASX:AHE) Shares Up 7% Today?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Adheris Health (ASX:AHE) shares were up 7.14% at $0.015 at 12:04 pm on 23 October 2026, while the S&P/ASX 200 was down 0.35%.
FY26 revenue was $34.0 million, down 46%, with a statutory net loss after tax of $4.3 million and cash of $9.5 million with no debt.
The CY27 pipeline has more than 90 programs, with nearly 60% of value in THRiV and digital engagement programs.

Shares in Adheris Health Limited (ASX:AHE) were up 7.14% at $0.015 during the trading session on 23 October 2026, as at 12:04 pm, while the S&P/ASX 200 stood at 8,762.60, down 0.35% (30.60 points). Adheris Health, formerly MedAdvisor, provides patient engagement and medication adherence programs for pharmaceutical manufacturers, pharmacies and healthcare organisations. Its latest update is the FY26 results announcement dated 31 August 2026, covering the 12 months ended 30 June 2026.

FY26 Results Show Lower Revenue and Reduced Costs

In its results announcement dated 31 August 2026, Adheris reported FY26 revenue of $34.0 million, down 46% from $63.0 million, reflecting lower customer renewals during the prior pharma budget period and lower bookings in the first half. Gross profit fell 56% to $14.6 million and gross margin eased from 52% to 43%.

Underlying EBITDA was a loss of $16.5 million, compared with a loss of $13.6 million a year earlier. Operating expenses fell 37%, from $49.8 million to $31.3 million. The statutory net loss after tax was $4.3 million, against $60.2 million in FY25, with significant items including a $15.7 million profit on the sale of the ANZ business and $3.7 million of early debt discharge costs.

Revenue Mix, Cash Position and Pipeline

The announcement dated 31 August 2026 stated that non-vaccine revenue rose from 54% to 83% of the total. GLP-1 medication revenue increased 34.9% and made up 8% of revenue, against 4% previously, while specialty medication revenue rose 19.2% to 21% of revenue. The company reported cash flow break-even in the fourth quarter of FY26 and cash at bank of $9.5 million with no debt.

The calendar 2027 pharma planning cycle is under way. The pipeline comprises more than 90 programs across nearly 40 customers and about 80 brands, with no single program or brand above 10% of value. Nearly 60% of pipeline value relates to THRiV and digital engagement programs, compared with 32% of FY26 revenue.

Mindsprint Proceedings and Jonas Earnout

The 31 August 2026 announcement also described proceedings commenced by Mindsprint Pte. Ltd. against subsidiary Adheris LLC in the United States District Court for the Southern District of New York. Mindsprint alleges breach of contract and claims damages of not less than US$2.3 million plus costs. Adheris disputes the claims and intends to defend them.

Finalisation of the first-year earnout payment from Jonas Software AUS Pty Ltd, the buyer of the ANZ business, is expected in the first quarter of FY27, with payment in the second quarter of FY27.

About the Company and Business Overview

Adheris Health Limited is listed on the ASX under the code AHE, with its registered office in Camberwell, Victoria, and describes itself as a business with more than 30 years of experience and a network of 170 million patients. It combines precision segmentation and predictive analytics to support patients through their treatment journey, including onboarding, education, medication adherence and refill support.

Its platform, THRiV, adapts each patient's experience in real time. The company completed the sale of its ANZ business to Jonas Software AUS Pty Ltd on 4 July 2025, so FY26 figures are presented for continuing operations. During FY26 it onboarded 11 new brands and reported SMS click-through rates averaging over 24%.

Related Sector Context

Adheris operates in healthcare services and technology, where patient engagement programs are typically commissioned by pharmaceutical companies through annual budget cycles. The company described the pharma budget cycle as its peak selling season, so bookings can be concentrated in particular months.

At 12:04 pm on 23 October 2026, the S&P/ASX 200 stood at 8,762.60, down 0.35%, while Adheris shares were up 7.14% at $0.015.

Risks to Weigh In

The announcement dated 31 August 2026 notes that FY26 revenue and profitability were affected by lower customer renewals and bookings in the previous budget cycle. The company reported an underlying EBITDA loss of $16.5 million and said cash flow generation is likely to be uneven from quarter to quarter in CY27.

The Mindsprint proceedings are at an early stage, and the company does not consider it possible to reliably quantify any financial impact. Product mix continued to lean toward legacy tactics in FY26, with underlying product margin at 51% compared with 57% a year earlier.

Catalysts on Watch

The announcement points to decisions on most of the CY27 pipeline expected by December 2026, with an update on pipeline conversion due at the Annual General Meeting in November 2026. The first-year Jonas earnout is expected to be finalised in the first quarter of FY27 and paid in the second quarter.

Where Things Stand

Adheris shares were up 7.14% at $0.015 at 12:04 pm on 23 October 2026. The most recent update, dated 31 August 2026, shows revenue of $34.0 million, cash of $9.5 million with no debt, and a CY27 pipeline that management expects to resolve largely by December 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.